• Je něco špatně v tomto záznamu ?

Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?

DP. Funda, L. Palová-Jelínková, J. Goliáš, Z. Kroulíková, A. Fajstová, T. Hudcovic, R. Špíšek,

. 2019 ; 10 (-) : 967. [pub] 20190514

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025854

Grantová podpora
NV16-27994A MZ0 CEP - Centrální evidence projektů

Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various tolDCs approaches obtained from animal (mainly NOD) models of T1D with a focus on parameters of this cell-based therapy such as protocols of tolDC preparation, antigen-specific vs. unspecific approaches, doses of tolDCs and/or autoantigens, application schemes, application routes, the migration of tolDCs as well as their preventive, early pre-onset intervention or curative effects. This review also discusses perspectives of tolDC therapy and areas of preclinical research that are in need of better clarification in animal models in a quest for effective and optimal tolDC therapies of T1D in humans.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025854
003      
CZ-PrNML
005      
20211208102422.0
007      
ta
008      
201125s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2019.00967 $2 doi
035    __
$a (PubMed)31139178
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Funda, David P $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
245    10
$a Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models? / $c DP. Funda, L. Palová-Jelínková, J. Goliáš, Z. Kroulíková, A. Fajstová, T. Hudcovic, R. Špíšek,
520    9_
$a Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various tolDCs approaches obtained from animal (mainly NOD) models of T1D with a focus on parameters of this cell-based therapy such as protocols of tolDC preparation, antigen-specific vs. unspecific approaches, doses of tolDCs and/or autoantigens, application schemes, application routes, the migration of tolDCs as well as their preventive, early pre-onset intervention or curative effects. This review also discusses perspectives of tolDC therapy and areas of preclinical research that are in need of better clarification in animal models in a quest for effective and optimal tolDC therapies of T1D in humans.
650    _2
$a zvířata $7 D000818
650    _2
$a dendritické buňky $x imunologie $x transplantace $7 D003713
650    _2
$a diabetes mellitus 1. typu $x imunologie $7 D003922
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a imunologická tolerance $x imunologie $7 D007108
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední NOD $7 D016688
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Palová-Jelínková, Lenka $u SOTIO a s., Prague, Czechia. Department of Immunology, 2nd Medical School, Charles University, Prague, Czechia.
700    1_
$a Goliáš, Jaroslav $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
700    1_
$a Kroulíková, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
700    1_
$a Fajstová, Alena $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia.
700    1_
$a Hudcovic, Tomáš, $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia. $d 1965- $7 xx0267225
700    1_
$a Špíšek, Radek $u SOTIO a s., Prague, Czechia. Department of Immunology, 2nd Medical School, Charles University, Prague, Czechia.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 967
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31139178 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20211208102420 $b ABA008
999    __
$a ok $b bmc $g 1599999 $s 1116540
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 967 $e 20190514 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
GRA    __
$a NV16-27994A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace